Analysts Set Sight Sciences, Inc. (NASDAQ:SGHT) Target Price at $4.67

Shares of Sight Sciences, Inc. (NASDAQ:SGHT) have been assigned an average recommendation of “Hold” from the eight research firms that are currently covering the firm, MarketBeat Ratings reports. One research analyst has rated the stock with a sell rating, four have issued a hold rating and three have assigned a buy rating to the company. The average 12 month target price among brokers that have issued a report on the stock in the last year is $4.6667.

SGHT has been the topic of a number of recent research reports. Lake Street Capital increased their target price on Sight Sciences from $5.00 to $7.00 and gave the stock a “buy” rating in a research note on Tuesday, October 21st. Needham & Company LLC restated a “hold” rating on shares of Sight Sciences in a research note on Thursday, August 28th. Morgan Stanley raised their price objective on Sight Sciences from $3.00 to $4.00 and gave the stock an “equal weight” rating in a research note on Tuesday, July 15th. Weiss Ratings restated a “sell (d-)” rating on shares of Sight Sciences in a research note on Wednesday, October 8th. Finally, Citigroup lowered their price objective on Sight Sciences from $4.50 to $4.00 and set a “neutral” rating on the stock in a research note on Tuesday, October 7th.

Insiders Place Their Bets

In other Sight Sciences news, CEO Paul Badawi sold 24,441 shares of the firm’s stock in a transaction on Wednesday, October 1st. The stock was sold at an average price of $3.34, for a total value of $81,632.94. Following the sale, the chief executive officer owned 5,962,502 shares of the company’s stock, valued at approximately $19,914,756.68. This trade represents a 0.41% decrease in their position. The sale was disclosed in a document filed with the SEC, which can be accessed through the SEC website. Also, insider Jeremy B. Hayden sold 9,731 shares of the firm’s stock in a transaction on Friday, October 3rd. The shares were sold at an average price of $3.27, for a total value of $31,820.37. Following the completion of the sale, the insider directly owned 256,590 shares in the company, valued at approximately $839,049.30. This represents a 3.65% decrease in their position. The SEC filing for this sale provides additional information. In the last ninety days, insiders sold 40,796 shares of company stock worth $135,173. Company insiders own 30.90% of the company’s stock.

Institutional Investors Weigh In On Sight Sciences

A number of large investors have recently modified their holdings of the business. Americana Partners LLC boosted its holdings in shares of Sight Sciences by 42.4% in the 3rd quarter. Americana Partners LLC now owns 1,229,819 shares of the company’s stock valued at $4,231,000 after purchasing an additional 365,901 shares in the last quarter. Tower Research Capital LLC TRC boosted its holdings in shares of Sight Sciences by 32.7% in the 2nd quarter. Tower Research Capital LLC TRC now owns 11,665 shares of the company’s stock valued at $48,000 after purchasing an additional 2,875 shares in the last quarter. Jane Street Group LLC acquired a new stake in shares of Sight Sciences in the 2nd quarter valued at $148,000. B Group Inc. boosted its holdings in shares of Sight Sciences by 11.6% in the 2nd quarter. B Group Inc. now owns 930,000 shares of the company’s stock valued at $3,841,000 after purchasing an additional 96,400 shares in the last quarter. Finally, Panagora Asset Management Inc. acquired a new stake in shares of Sight Sciences in the 2nd quarter valued at $132,000. Institutional investors and hedge funds own 55.51% of the company’s stock.

Sight Sciences Stock Down 2.5%

NASDAQ:SGHT opened at $5.04 on Monday. Sight Sciences has a 1 year low of $2.03 and a 1 year high of $5.48. The company has a current ratio of 10.01, a quick ratio of 9.49 and a debt-to-equity ratio of 0.57. The stock has a market cap of $263.93 million, a price-to-earnings ratio of -5.25 and a beta of 2.41. The stock has a 50-day moving average price of $3.88 and a two-hundred day moving average price of $3.70.

Sight Sciences (NASDAQ:SGHT) last posted its quarterly earnings data on Wednesday, September 8th. The company reported ($0.81) earnings per share for the quarter. The firm had revenue of $12.54 million for the quarter. Sight Sciences had a negative return on equity of 59.38% and a negative net margin of 64.23%. As a group, equities analysts expect that Sight Sciences will post -0.99 earnings per share for the current year.

Sight Sciences Company Profile

Sight Sciences, Inc, an ophthalmic medical device company, engages in the development and commercialization of surgical and nonsurgical technologies for the treatment of eye diseases. It operates through two segments, Surgical Glaucoma and Dry Eye. The company's products include OMNI Surgical System, an implant-free glaucoma surgery technology indicated to reduce intraocular pressure in adult patients with primary open-angle glaucoma; and SION Surgical Instrument, a manually operated device used in ophthalmic surgical procedures to excise trabecular meshwork.